FDA Snubs Ozempic and Similar Drugs from Key Compounding List
Published Date: 5/1/2026
Notice
Summary
The FDA is updating a special list of important drug ingredients that compounding pharmacies can use to make medicines. They decided not to add three popular drugs—semaglutide, tirzepatide, and liraglutide—to this list right now. People and companies have until June 30, 2026, to share their thoughts, which could affect future drug availability and costs.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 2 costs, 1 mixed.
Three Drugs Not Added Now
The FDA proposes NOT to add semaglutide, tirzepatide, and liraglutide to the Section 503B Bulks List. That means outsourcing compounding facilities may not lawfully compound using those bulk drug substances unless the substance later appears on the 503B Bulks List or the drug product is on FDA's drug shortage list at the time of compounding.
What FDA Won't Count As 'Clinical Need'
When deciding whether a bulk drug substance belongs on the 503B Bulks List, FDA says it will not treat supply issues (such as backorders), convenience of administration, or the cost of a compounded product versus an FDA-approved product as a basis for 'clinical need.'
Public Comment Deadline Set
FDA is accepting electronic or written comments on this notice through June 30, 2026. Stakeholders must submit comments by 11:59 p.m. Eastern Time on June 30, 2026 for them to be considered.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13616 — Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
The FDA is officially pulling the plug on 34 drug approvals because the companies stopped selling these medicines. This change kicks in on August 5, 2026, and it mainly affects drug makers like Endo Operations and Pfizer. No money penalties here—just a clean break, but companies can ask to reapply if they want to bring the drugs back.
2026-13492 — Determination That VASOPRESSIN IN SODIUM CHLORIDE (vasopressin) 0.9%, Injection, 50 units/50 milliliters (1 unit/milliliters) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has confirmed that vasopressin in sodium chloride (0.9%, injection) wasn’t taken off the market because of safety or effectiveness problems. This means generic versions can now get approved if they meet all the rules, helping patients and healthcare providers get more options. No changes in price or availability are expected right now, but more generics could be coming soon!
2026-13519 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Premarket Approval of Medical Devices
The FDA is asking for public feedback on their paperwork rules for approving the most important and risky medical devices, like life-support machines. This review helps keep devices safe and effective before they hit the market. If you have thoughts, you’ve got until August 5, 2026, to share them—no cost changes, just a check-in on the info they collect.
2026-13534 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Practices and Procedures; Formal Hearings
The FDA is asking for public feedback on how it collects information for formal hearings and administrative rules. This affects businesses and people who interact with the FDA, with no new costs but a chance to improve paperwork processes. Comments are due by August 5, 2026, so don’t miss your chance to weigh in!
2026-13533 — Agency Information Collection Activities; Proposed Collection; Comment Request; Biologics License Applications, Procedures and Requirements
The FDA wants your thoughts on how it collects info for biologics license applications—basically, the paperwork needed to approve new biological medicines. This affects companies making these medicines and anyone involved in the approval process. You’ve got until September 4, 2026, to share your comments, so don’t miss out on shaping the rules and possibly saving time and money!
Previous / Next Documents
Previous: 2026-08551 — Florida Power and Light Company; St. Lucie Plant, Units 1 and 2; Subsequent License Renewal and Record of Decision
Florida Power and Light just got the green light to keep running its St. Lucie nuclear plant, Units 1 and 2, for even longer! This means the plant can keep providing power safely and reliably, helping Florida’s energy needs without interruption. The new licenses were officially issued on April 28, 2026, ensuring steady energy and supporting local jobs without extra costs to customers right now.
Next: 2026-08553 — Supply Chain Gaps and Entrepreneur Assistance
The SBA wants your ideas on how to fix supply chain problems in important industries and help entrepreneurs grow with better tech support. Small businesses and startups are the stars here, and your feedback by May 18, 2026, will shape new programs to boost innovation and keep the U.S. competitive. No money is offered for comments, but your voice could spark big changes!